These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 5556189)

  • 1. Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients.
    Kirby WM; De Maine JB; Serrill WS
    Postgrad Med J; 1971 Feb; 47():Suppl:41-6. PubMed ID: 5556189
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of cefazolin, a new cephalosporin antibiotic, in normal and uraemic patients.
    Leroy A; Canonne MA; Fillastre JP; Humbert G
    Curr Ther Res Clin Exp; 1974 Sep; 16(9):878-89. PubMed ID: 4214662
    [No Abstract]   [Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of cefazolin in normal and uremic subjects.
    Welling PG; Craig WA; Gordon AL; Kunin CM
    Clin Pharmacol Ther; 1974 Apr; 15(4):344-53. PubMed ID: 4821438
    [No Abstract]   [Full Text] [Related]  

  • 5. [Plasma half life of a new cephalosporin in uremic patients].
    Fillastre JP; Humbert G; Malandain H; Dubois D; Daufresne MF; Robert M
    J Urol Nephrol (Paris); 1973; 79(4):384. PubMed ID: 4720136
    [No Abstract]   [Full Text] [Related]  

  • 6. Insulin catabolism in chronic uraemia and in anephric man before and after dialysis treatment.
    Navalesi R; Pilo A; Maggiore Q; Lenzi S; Cecchetti P; Donato L
    Proc Eur Dial Transplant Assoc; 1972; 9():119-25. PubMed ID: 4668904
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics of dyphylline elimination by uremic patients.
    Lee CC; Wang LH; Majeske BL; Marbury TC
    J Pharmacol Exp Ther; 1981 May; 217(2):340-4. PubMed ID: 7229976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefamandole kinetics in uremic patients undergoing hemodialysis.
    Gambertoglio JG; Aziz NS; Lin ET; Grausz H; Naughton JL; Benet LZ
    Clin Pharmacol Ther; 1979 Nov; 26(5):592-9. PubMed ID: 498702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of cephalexin in renal insufficiency.
    Regamey C; Humair L
    Postgrad Med J; 1971 Feb; 47():Suppl:69-78. PubMed ID: 5556195
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics and hemodialyzability of cefazolin in uremic patients.
    Craig CP; Rifkin SI
    Clin Pharmacol Ther; 1976 Jun; 19(6):825-9. PubMed ID: 773590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of intravenous cefotaxime in patients undergoing chronic hemodialysis.
    Chodos J; Francke EL; Saltzman M; Neu HC
    Ther Drug Monit; 1981; 3(1):71-4. PubMed ID: 6262952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profound mishandling of protein glycation degradation products in uremia and dialysis.
    Agalou S; Ahmed N; Babaei-Jadidi R; Dawnay A; Thornalley PJ
    J Am Soc Nephrol; 2005 May; 16(5):1471-85. PubMed ID: 15800128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology of cephalexin administered intravenously.
    De Maine JB; Kirby WM
    Antimicrob Agents Chemother (Bethesda); 1970; 10():190-4. PubMed ID: 5521336
    [No Abstract]   [Full Text] [Related]  

  • 14. An extravenal mechanism for the maintenance of potassium balance in severe chronic renal failure.
    Hayes CP; McLeod ME; Robinson RR
    Trans Assoc Am Physicians; 1967; 80():207-16. PubMed ID: 6082243
    [No Abstract]   [Full Text] [Related]  

  • 15. Cefsulodin pharmacokinetics during hemodialysis.
    Matzke GR; Keane WF
    Trans Am Soc Artif Intern Organs; 1982; 28():324-8. PubMed ID: 7164256
    [No Abstract]   [Full Text] [Related]  

  • 16. The analysis of concentration dependence of uremic lesions in clinical studies.
    Sargent JA; Gotch FA
    Kidney Int Suppl; 1975 Jan; (2):35-44. PubMed ID: 1057691
    [No Abstract]   [Full Text] [Related]  

  • 17. Determination of plasma and renal clearance of cefuroxime and its pharmacokinetics in renal insufficiency.
    van Dalen R; Vree TB; Hafkenscheid JC; Gimbrère JS
    J Antimicrob Chemother; 1979 May; 5(3):281-92. PubMed ID: 479064
    [No Abstract]   [Full Text] [Related]  

  • 18. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis.
    Don BR; Spin G; Nestorov I; Hutmacher M; Rose A; Kaysen GA
    J Pharm Pharmacol; 2005 Nov; 57(11):1407-13. PubMed ID: 16259772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uremic toxins: a new focus on an old subject.
    Yavuz A; Tetta C; Ersoy FF; D'intini V; Ratanarat R; De Cal M; Bonello M; Bordoni V; Salvatori G; Andrikos E; Yakupoglu G; Levin NW; Ronco C
    Semin Dial; 2005; 18(3):203-11. PubMed ID: 15934967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
    Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.